Monkeypox, also known as mpox, is a virus that typically causes symptoms like skin rashes, mouth "ulcers," fevers, and head and muscle aches that last for 2 to 4 weeks. Through personal contact with an infected person, animal, or contaminated surface, mumps can be passed from one person to another.

 

Although primarily Central and Western Africa has historically seen the majority of instances of monkeypox, a global return in 2022 has made monkeypox a major health concern. In May 2022, the UK saw the first case of the new pandemic. Following this, other cases of monkeypox were identified in over 90 different nations, including a total of 124 cases in South Korea. The World Health Organization (WHO) immediately declares the outbreak a Public Health Emergency of International Concern due to the unexpected increase in monkeypox cases. 

 

 

https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html

 

 

What’s more concerning is the current lack of approved specific treatment for monkeypox patients. However, immunizations are an option as a preventative step even though there are no known therapy options for after-virus contraction. The best approach to avoid monkeypox is to get vaccinated as well as practice preventative measures like limiting physical contact and maintaining good cleanliness. It's interesting to note that this vaccine was initially developed by the Danish biotech company Bavarian Nordic to fight the smallpox virus before it was authorized for use in the prevention of monkeypox. Bavarian Nordic presently provides all immunizations worldwide and experiences a tremendous demand for its 2-dose JYNNEOS vaccine, which it manufactures exclusively.